Leerink Partnrs Has Pessimistic Outlook of A Q2 Earnings

Agilent Technologies, Inc. (NYSE:A) – Research analysts at Leerink Partnrs decreased their Q2 2025 EPS estimates for shares of Agilent Technologies in a research report issued on Thursday, February 27th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings per share of $1.27 for the quarter, down from their previous estimate of $1.32. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q2 2026 earnings at $1.39 EPS, Q3 2026 earnings at $1.51 EPS, FY2026 earnings at $6.05 EPS and FY2027 earnings at $6.60 EPS.

Several other analysts also recently commented on the stock. Citigroup increased their target price on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a report on Thursday, December 19th. JPMorgan Chase & Co. dropped their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 26th. Bank of America cut their target price on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Robert W. Baird reduced their price objective on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Sanford C. Bernstein lowered their target price on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research note on Tuesday, November 26th. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $146.15.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $127.07 on Friday. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. The stock has a market cap of $36.25 billion, a PE ratio of 29.21, a price-to-earnings-growth ratio of 3.64 and a beta of 1.07. The stock’s fifty day simple moving average is $140.78 and its two-hundred day simple moving average is $139.20. Agilent Technologies has a 1-year low of $124.16 and a 1-year high of $155.35.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.58% and a net margin of 19.27%. The company had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.67 billion.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Flynn Zito Capital Management LLC lifted its position in Agilent Technologies by 3.8% during the fourth quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company’s stock valued at $251,000 after purchasing an additional 69 shares during the last quarter. IFP Advisors Inc lifted its holdings in shares of Agilent Technologies by 17.7% in the 4th quarter. IFP Advisors Inc now owns 458 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 69 shares during the last quarter. Tiemann Investment Advisors LLC grew its position in Agilent Technologies by 5.6% in the fourth quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company’s stock worth $191,000 after acquiring an additional 75 shares in the last quarter. Brown Brothers Harriman & Co. grew its position in Agilent Technologies by 13.5% in the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after acquiring an additional 77 shares in the last quarter. Finally, Rothschild Investment LLC increased its stake in Agilent Technologies by 19.2% during the fourth quarter. Rothschild Investment LLC now owns 491 shares of the medical research company’s stock worth $66,000 after acquiring an additional 79 shares during the last quarter.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the transaction, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at $5,947,800. This trade represents a 4.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be issued a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date of this dividend is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.